Skip to main content

Advertisement

SpringerLink
Log in

Society of behavioral medicine supports increasing HPV vaccination uptake: an urgent opportunity for cancer prevention

  • Policy Brief
  • Published:
Translational Behavioral Medicine

Abstract

Human papillomavirus (HPV) vaccine coverage remains low in the USA. The Society for Behavioral Medicine (SBM) supports the goals outlined by Healthy People 2020, the President’s Cancer Panel, and the National Vaccine Advisory Committee to increase vaccination coverage among both males and females. SBM makes the following recommendations in support of efforts to reduce structural and other barriers to HPV vaccination services in order to increase rates of series completion. We encourage legislators and other policymakers to improve administration authority, insurance coverage, and reimbursement rates to healthcare providers who make the HPV vaccine available to adolescents; provide instrumental support to fund the development of school curricula on HPV vaccination; and increase public awareness that HPV vaccination can prevent cancer. We urge healthcare providers and healthcare systems to increase the strength, quality, and consistency of HPV vaccination recommendations for all eligible patients; to treat HPV vaccination as a routine preventive service; employ culturally appropriate communication strategies in clinical settings to educate eligible patients, parents, and guardians about the importance, effectiveness, and safety of HPV vaccination; and to strengthen and better coordinate the use of electronic medical records and immunization information systems.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Satterwhite, C. L., et al. (2013). Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis, 40(3), 187–193.

    Article  PubMed  Google Scholar 

  2. Human, O. (2012). From the Centers for Disease Control and Prevention. JAMA, 308(5), 445.

    Google Scholar 

  3. Bosch, F. X., et al. (1995). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst, 87(11), 796–802.

    Article  CAS  PubMed  Google Scholar 

  4. Walboomers, J. M., et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189(1), 12–19.

    Article  CAS  PubMed  Google Scholar 

  5. Maxwell, J.H., J.R. Grandis, and R.L. Ferris, HPV-associated head and neck cancer: unique features of epidemiology and clinical management. Medicine. 2016; 67.

  6. Alemany, L., et al., Role of human papillomavirus in penile carcinomas worldwide. Eur Urol. 2016.

  7. Park, I. U., Introcaso, C., & Dunne, E. F. (2015). Human papillomavirus and genital warts: a review of the evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis, 61(suppl 8), S849–S855.

    Article  PubMed  Google Scholar 

  8. De Vuyst, H., et al. (2009). Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer, 124(7), 1626–1636.

    Article  CAS  PubMed  Google Scholar 

  9. Jemal, A., et al., Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)–associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013: djs491.

  10. Marur, S., et al. (2010). HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol, 11(8), 781–789.

    Article  PubMed  Google Scholar 

  11. Rimer, B., Harper, H., & Witte, O. (2014). Accelerating HPV vaccine uptake: urgency for action to prevent cancer; a report to the President of the United States from the president’s cancer panel. Bethesda, MD: National Cancer Institute.

    Google Scholar 

  12. Schiffman, M., & Castle, P. E. (2005). The promise of global cervical-cancer prevention. N Engl J Med, 353(20), 2101–2104.

    Article  CAS  PubMed  Google Scholar 

  13. Food, U., D. Administration, and F. approves Gardasil, for prevention of certain cancers caused by five additional types of HPV on December 10, 2014.

  14. Monie, A., et al. (2008). Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics: Targets & Therapy, 2(1), 107.

    CAS  Google Scholar 

  15. Control, C.f.D. and Prevention (2010). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep, 59(20), 630.

    Google Scholar 

  16. Petrosky, E., et al. (2015). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR, 64, 300–304.

    PubMed  Google Scholar 

  17. Recommendations, H.V (2012). Commite on infectious disease. Pediatrics, 129, 602–605.

    Article  Google Scholar 

  18. Kahn, J. A., et al. (2012). Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics, 130(2), e249–e256.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Villa, L., et al. (2006). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer, 95(11), 1459–1466.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Reagan-Steiner, S., et al. (2015). National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years–United States, 2014. MMWR Morb Mortal Wkly Rep, 64(29), 784–792.

    Article  PubMed  Google Scholar 

  21. Ng, J., et al. (2014). Human papillomavirus vaccination coverage among female adolescents in managed care plans—United States, 2013. MMWR. Morb Mortal Wkly Rep, 64(42), 1185–1189.

    Article  Google Scholar 

  22. Berkowitz, Z., et al. (2015). Providers’ beliefs about the effectiveness of the HPV vaccine in preventing cancer and their recommended age groups for vaccination: findings from a provider survey, 2012. Prev Med, 81, 405–411.

    Article  CAS  PubMed  Google Scholar 

  23. Roland, K. B., et al. (2014). Primary care providers human papillomavirus vaccine recommendations for the medically underserved: a pilot study in US federally qualified health centers. Vaccine, 32(42), 5432–5435.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Gilkey, M. B., et al. (2015). Quality of physician communication about human papillomavirus vaccine: findings from a national survey. Cancer Epidemiol Biomark Prev, 24(11), 1673–1679.

    Article  Google Scholar 

  25. Gilkey, M. B., et al. (2016). Provider communication and HPV vaccination: the impact of recommendation quality. Vaccine, 34(9), 1187–1192.

    Article  PubMed  Google Scholar 

  26. Holman, D. M., et al. (2014). Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr, 168(1), 76–82.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Dorell, C., et al. (2013). Factors that influence parental vaccination decisions for adolescents, 13 to 17 years old national immunization survey–Teen, 2010. Clin Pediatr, 52(2), 162–170.

    Article  Google Scholar 

  28. Kessels, S. J., et al. (2012). Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine, 30(24), 3546–3556.

    Article  PubMed  Google Scholar 

  29. Services, U.S.D.o.H.a.H. Healthy People 2020. 2016 [cited 2016 January 25]; Available from: https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives.

  30. Btoush, R. M., et al. (2015). Initiation of human papillomavirus vaccination among predominantly minority female and male adolescents at inner-city community health centers. Am J Public Health, 105(11), 2388–2396.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to gratefully acknowledge the expert review provided by the Society of Behavioral Medicine’s Health Policy Committee, the Scientific and Professional Liaison Council, and the Cancer Special Interest Group.

Author information

Authors and Affiliations

  1. Division of Epidemiology and Biostatistics (MC923), School of Public Health, University of Illinois at Chicago, 1603 West Taylor Street, Room 888, Chicago, IL, 60612, USA

    Caryn E. Peterson PhD

  2. University of Illinois at Chicago, Chicago, IL, USA

    J. Andrew Dykens MD, Joanna Buscemi PhD, Karriem Watson MPH, MS & Marian Fitzgibbon PhD

  3. University of North Carolina, Chapel Hill, NC, USA

    Noel T. Brewer PhD

  4. Governors State University, University Park, IL, USA

    DeLawnia Comer-Hagans PhD & Zo Ramamonjiarivelo PhD

Authors
  1. Caryn E. Peterson PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Andrew Dykens MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noel T. Brewer PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joanna Buscemi PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Karriem Watson MPH, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. DeLawnia Comer-Hagans PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zo Ramamonjiarivelo PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marian Fitzgibbon PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caryn E. Peterson PhD.

Ethics declarations

As a policy brief, this manuscript was not supported by any study funding, nor was there data collected or IRB approval sought. The following statements do not apply to this Policy Brief: Human Rights, Welfare of animals, Informed Consent, Helsinki or comparable standard statement.

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

The content of this Policy Brief have not been previously published and manuscript has not been submitted elsewhere.

Implications

Practice: Healthcare providers and healthcare systems should improve patient education and communication, clinical standards of practice, and information systems to ensure eligible female and male patients initiate and complete the full HPV vaccination series.

Policy:Legislators and policy makers should ensure adequate resources to achieve the HPV vaccination goals by advocating for improved coverage and reimbursement for providers, optimized school curricula and role in vaccination-related activities, and increased public awareness.

Research: SBM encourages the initiation of studies employing implementation science methodologies to identify behavioral and systems strategies for addressing both supply-side and demand side barriers to HPV vaccination uptake and series completion.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peterson, C.E., Dykens, J.A., Brewer, N.T. et al. Society of behavioral medicine supports increasing HPV vaccination uptake: an urgent opportunity for cancer prevention. Behav. Med. Pract. Policy Res. 6, 672–675 (2016). https://doi.org/10.1007/s13142-016-0441-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13142-016-0441-5

Keywords

Search

Navigation